Compare NUVB & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVB | CMPS |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2020 | 2020 |
| Metric | NUVB | CMPS |
|---|---|---|
| Price | $5.73 | $13.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $11.38 | ★ $25.38 |
| AVG Volume (30 Days) | ★ 4.6M | 2.3M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,902,000.00 | N/A |
| Revenue This Year | $203.82 | N/A |
| Revenue Next Year | $58.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 698.96 | N/A |
| 52 Week Low | $3.00 | $4.82 |
| 52 Week High | $9.75 | $15.87 |
| Indicator | NUVB | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 57.43 |
| Support Level | $5.28 | $12.95 |
| Resistance Level | $6.25 | $14.87 |
| Average True Range (ATR) | 0.29 | 0.74 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 12.06 | 57.71 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.